P&G PATENT

. Hodorin- O.	II S Botans in a	Approved for use through 07/31/2006, OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no persons are request	uired to respond to a collection of it	Trademark Office; U.S. DEPARTMENT OF COMMERCE from unless it contains a valid OMB control number.
Request For	Application Number	09/849,963
Continued Examination (RCE)	Filing Date	may 4, 2001
Transmittal Address to:	First Named Inventor	Deak
Mail Stop RCE Commissioner for Patents	Art Unit	1251
P.O. Box 1450	Examiner Name	Charles Boyer
Alexandria, VA 22313-1450	Attorney Docket Numb	
This is a Request for Continued Examination (RCE) at Request for Continued Examination (RCE) practice under 37 CF 1995, or to any design application. See Instruction Sheet for RC Submission required under 37 CFR 1.114) Not amendments enclosed with the RCE will be entered in the applicant does not wish to have any previously filed unent amendment(s).  Previously submitted. If a final Office action is o considered as a submission even if this box is not submission.	Es (not to be submitted to the e: If the RCE is proper, any pn e order in which they were filed ered amendment(s) entered, a	above-identified application.  I utility or plant application filed prior to June 8, USPTO) on page 2,  sviously filed unentered amendments and unless applicant instructs otherwise. If applicant must request non-entry of such
i. Consider the arguments in the Appeal Brid		
b Enclosed  i Amendment/Reply  ii Affidavit(s)/ Declaration(s)  2 Miscellaneous  a Suspension of action on the above-identified apperiod of months. (Period of suspension b Other	iv Other	on Disclosure Statement (IDS)  OFR 1.103(c) for a nder 37 CFR 1.17(i) required)
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to  i. RCE fee required under 37 CFR 1.17(e)		
ii. Extension of time fee (37 CFR 1.136 and 1.17) iii. Other		
b. Check in the amount of \$		
c. Payment by credit card (Form PTO-2038 enclosed)	enclosed	·
WARNING: Information on this town		
and another and another and authorization on PTO-2038		
SIGNATURE OF APPLICANT, Signature  CAROLINE WEI-BERI	ATTORNEY, OR AGENT RE	QUIRED
Signature Constine Wo Acad	, (CA12(16)	OCHOBER R, 2003
CPRTIFICATE OF MAILING AT TO		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope Office on the date shown below.  Name (Print/Type)  CARDLINE WEL-BERK  Signature		
This collection as information in the DIA II There	Date	Oct-1- 8 2002
This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.		
Tooler Tools and select option 2.		

## Certification of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Patcut and Trademark Office on the date shown below.

Name of Aponery Date Reg. No.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of

Deak et al. Serial No. 09/849,963 Confirmation No. 9317

Filed: May 4, 2001

Group Art Unit:1751

Examiner: Charles Boyer

Title: PROCESS FOR TREATING A LIPOPHILIC FLUID

Commissioner for Patents
Mail Stop RCE
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

## REQUEST FOR CONTINUING EXAMINATION

This is a complete response to the Final Office Action mailed July 8, 2003, Applicants respectfully request that the Examiner continue examination of the present application in view of the present amendments and accompanying remarks.

## **AMENDMENTS**

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 5 of this paper.